Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays
Portfolio Pulse from Vandana Singh
Theratechnologies Inc. (NASDAQ:THTX) warns of a potential supply disruption for its drug Egrifta SV due to a manufacturing facility shutdown. This could lead to a $1.6 million revenue shortfall in 2024. The company is working with the FDA and its manufacturer to minimize impact.
September 19, 2024 | 4:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Theratechnologies faces a potential supply disruption for Egrifta SV due to a manufacturing facility shutdown, risking a $1.6 million revenue shortfall in 2024. The company is working with the FDA and its manufacturer to minimize impact.
The potential supply disruption of Egrifta SV, a key product for Theratechnologies, due to manufacturing delays could negatively impact revenues by $1.6 million in 2024. This news is likely to affect investor sentiment negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100